Neuronetrix will revolutionize the treatment of patients with neurologic disorders by providing meaningful diagnostic information to health care practitioners early in the disease process.
We will do this by becoming the world’s innovator and leader in point-of-care neurological diagnostic services.BUSINESS OPPORTUNITY:
Alzheimer’s disease is a chronic neurodegenerative disease of the brain which afflicts roughly 5 million individuals in the United States. Approximately 10% of those over 65 and 50% of those over 85 will die as a result of Alzheimer’s disease.
Even with several therapies available to treat Alzheimer’s disease, there still is a significant gap between the onset of the disease and point at which treatment actually begins. This treatment gap is directly tied to the challenges in diagnosing the disease early, before the significant loss of memory, cognition, and activities of daily living. Patients, doctors, caregivers, and the pharmaceutical industry, are looking for and demanding a solution to this problem.
Neuronetrix' COGNISION™ System will, for the first time, directly detect the abnormal cognitive effects of Alzheimer’s disease! This will facilitate an earlier and more accurate diagnosis than is currently available. Physicians will use the COGNISION™ test to determine which patients would benefit from the available drug treatments. The system can also be used to monitor the efficacy of the prescribed therapy.
With the aging of America and the proliferation of new Alzheimer’s therapies, the market for Alzheimer’s screening could approach several billion dollars per year in the United States alone.
Following the validation of the COGNISION™ System for Alzheimer’s disease, Neuronetrix will expand into other neurodiagnostic markets such as traumatic brain injury (TBI), ADHD, dyslexia, and depression.
|ALZHEIMER'S DISEASE AND RELATED DEMENTIAS:|
Neuronetrix is initially targeting the diagnosis of Alzheimer’s disease and related dementias for the first clinical release of the COGNISION™ System. Alzheimer’s disease was selected because of four primary reasons; 1) the disease is devastating to those affected and their families, 2) several pharmaceutical companies are developing and/or marketing products which have proven beneficial to Alzheimer’s sufferers if prescribed in the early stages of the disease, 3) because of the new treatment options, the market for an early and accurate diagnostic test for Alzheimer’s is significant and growing, and 4) numerous ERP studies of Alzheimer’s have been performed, demonstrating a high likelihood of success with the COGNISION™ System.
The 2nd point regarding pharmaceuticals for Alzheimer’s disease demands a little more attention. All of the drugs currently approved for Alzheimer’s disease are neuroprotective in nature. This means they can protect brain cells from the disease but generally do not reverse the damage which has already been done. Therefore, for these drugs to be effective, the patient must begin treatment at the earliest confirmed sign of the disease. But, the symptoms present in Alzheimer’s disease are similar to and overlap with those found in other forms of dementia often leading to an inaccurate or nonspecific diagnosis. And since those drugs which target Alzheimer’s disease may be ineffective or even toxic to patients with other forms of dementia, it is critically important that the diagnostic test must accurately confirm a diagnosis of Alzheimer’s and exclude the other non-Alzheimer’s dementias.
Furthermore, a method to provide this early confirmatory diagnosis of Alzheimer’s is of the utmost importance to ensure marketing success for those pharmaceutical companies developing Alzheimer’s therapies.